In-article:

Achiko AG completes funding of 4.85 million Swiss francs and changes in management team


EQS-Ad-hoc: Achiko AG / Keyword (s): Funding
Achiko AG completes funding of 4.85 million Swiss francs and changes in management team

12.31.2021 / 06:45 CET / CEST
Event announcement within the meaning of art. 53 LR (SIX)
The content is the responsibility of the issuer.

Achiko AG completes funding of 4.85 million Swiss francs and changes in management team

– Finalization of an investment of 4.85 million Swiss francs initiated in August 2021.

– The director of the board of directors Christophe Laurent is stepping down.

– Appointment of Adam O’Keeffe as interim Financial Director.

Zurich, December 31, 2021 Event announcement according to art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) to conclude a financing transaction of 4.85 million Swiss francs with strategic investors which began in August 2021, and which includes the repayment of the current portion of its obligations to Yorkville Capital Management LLC, as well as the capital increase announced earlier this month.

The funding will be used to restructure operating costs and support the company’s commercialization of its unique healthcare technology ecosystem – an affordable, non-invasive AptameX rapid Covid-19 test.MD, integrated Teman SehatMD (Mon Aide-Sant), a digital passport solution deployed in Indonesia, as well as worldwide manufacturing and sales efforts upon completion of CE mark registration in the first quarter of 2022. Production of its kit Second-generation rapid test has started and the company is responding to inquiries and developing a sales pipeline in Indonesia as well as other parts of Asia and EMEA.

“We are immensely grateful for the support and trust we have received from all of our investors and shareholders,” said Steven Goh, CEO of Achiko. “It is evident that the Covid-19 will be present in the long term and that the diagnostic tests must be integrated in a response to the Covid-19 multiple levels with the vaccination and the antiviral treatments to limit the human and economic impacts. We wait. look forward to further advances in 2022, as our unique platform plays a vital role in how we conduct our daily lives and regain some semblance of normalcy. “

Finally, the company will update its board of directors at the start of 2022, with the withdrawal of Christophe Laurent, and the appointment of Adam O’Keeffe as interim CFO, following the decision of our previous director. Financier Robert Rieder to pursue opportunities in the private sector. Mr. O’Keeffe is a senior finance specialist with over 20 years of experience in the business services and tax industry. He has worked with leading technology and innovation companies specializing in health sciences, technology, artificial intelligence, biotechnology and manufacturing.

ABOUT ACHIKO AG
Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468; www.achiko.com) develops innovative diagnostic solutions that put people first. The company’s flagship product is a fast and reliable Covid-19 test, accompanied by an app offering a user-friendly digital health passport. The test and complementary application was launched in Indonesia in mid-2021 and an application for CE mark approval in Europe will be submitted in 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameXMD, and complementary health applications through its digital mobile health technology division, Teman SehatMD (My Health Aid). AptameX DNA aptamer tests can be rapidly synthesized chemically, are cost effective and have great potential in the diagnosis of several diseases. By leveraging AptameX and Teman Sehat, Achiko aims to provide rapid, accurate and affordable diagnostic tests for a range of pathogenic diseases and therapeutic indications in rapidly evolving health diagnostics.

Our head office is Zurich and we have offices in Hong Kong, Jakarta, Soul, and Singapore.

Media contacts:

ACHIKO AG
Investor Relations
E: [email protected]

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: [email protected]
T: +41 44 266 67 67

united states & Global
Jeanene Timberlake
Rooneypartners
E: [email protected]
T: +1 646 770 8858

Liability release
This press release expressly or impliedly contains certain forward-looking statements regarding Achiko AG and its activities. These statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from all future results, performances or accomplishments expressed or implied by such forward-looking statements. Achiko AG is providing this press release as of this date and does not undertake to update the forward-looking statements contained in this document as a result of new information, future events or otherwise.



Source link -88